| Market Capitalization (Millions $) |
37 |
| Shares
Outstanding (Millions) |
8 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
87 |
| Net Income (TTM) (Millions $) |
-10 |
| Cash Flow (TTM) (Millions $) |
17 |
| Capital Exp. (TTM) (Millions $) |
9 |
Business Description
Enzon Pharmaceuticals Inc is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative therapies for the treatment of cancer and other serious diseases. The company was founded in 1981 and is headquartered in Piscataway, New Jersey.
Enzon Pharmaceuticals has a unique approach to drug development, using a proprietary technology platform called PEGylation. PEGylation involves attaching polyethylene glycol (PEG) chains to therapeutic proteins or drug molecules, which can enhance their efficacy and prolong their circulation time in the body.
The company's product portfolio includes several PEGylated drugs that have been approved by regulatory authorities and are marketed in the United States and other countries. These drugs target a range of diseases, including breast cancer, lung cancer, and multiple myeloma.
In addition to its commercial products, Enzon Pharmaceuticals also has a robust pipeline of drug candidates in various stages of development. The company actively engages in strategic collaborations and partnerships to leverage its technology platform and expand its product portfolio.
Enzon Pharmaceuticals is committed to advancing patient care and improving outcomes. Through its innovative therapies and ongoing research efforts, the company strives to make a meaningful impact in the field of biopharmaceuticals.
Company Address: 333 East Butterfield Road, Suite 400 Lombard 60148 IL
Company Phone Number: 874-0700 Stock Exchange / Ticker: ENZN
|
%
2.53% 
124.86 %